Search research publications and outputs

  1. 2017
  2. 2016
  3. An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells

    Peitzsch, C., Cojoc, M., Hein, L., Kurth, I., Mӓbert, K., Trautmann, F., Klink, B., Schrock, E., Wirth, M. P., Krause, M., Stakhovsky, E. A., Telegeev, G. D., Novotny, V., Toma, M. I., Muders, M., Baretton, G. B., Frame, F. M., Maitland, N. J., Baumann, M. & Dubrovska, A. 16 Mar 2016

    Article in Cancer research

  4. Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow

    Miftakhova, R., Hedblom, A., Semenas, J., Robinson, B. D., Simoulis, A., Malm, J., Rizvanov, A., David Heery, D., Mongan, N. P., Maitland, N. J., Allegrucci, C. & Persson, J. L. 26 Feb 2016

    Article in Cancer research

  5. 2015
  6. miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α6 integrin expression

    Zoni, E., van der Horst, G., van de Merbel, A. F., Chen, L., Rane, J. K., Pelger, R. C. M., Collins, A. T., Visakorpi, T., Snaar-Jagalska, B. E., Maitland, N. J. & van der Pluijm, G. 1 Jun 2015

    Article in Cancer Research

  7. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

    Khanna, A., Rane, J. K., Kivinummi, K. K., Urbanucci, A., Helenius, M. A., Tolonen, T. T., Saramäki, O. R., Latonen, L., Manni, V., Pimanda, J. E., Maitland, N. J., Westermarck, J. & Visakorpi, T. 19 Apr 2015

    Article in Oncotarget

  8. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

    Santer, F. R., Erb, H. H. H., Oh, S. J., Handle, F., Feiersinger, G. E., Luef, B., Bu, H., Schäfer, G., Ploner, C., Egger, M., Rane, J. K., Maitland, N. J., Klocker, H., Eder, I. E. & Culig, Z. 20 Mar 2015

    Article in Oncotarget

  9. 2014
Previous 1 2 3 4 5 6 7 Next